GlassScriptPhysician profile
Jeffrey H Perlson
NPI 1740272079
$912.28
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $77.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169.07 | 2019 | |
| Amgen INC. | $108.01 | 2019 | |
| Lilly USA, LLC | $96.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $82.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $68.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.24 | 2019 | |
| Merck Sharp & Dohme LLC | $60.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.01 | 2019 | |
| Astellas Pharma US INC | $41.25 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.56 | 2019 | |
| Radius Health, INC. | $28.16 | 2019 | |
| Pfizer INC. | $23.64 | 2019 | |
| Bausch Health US, LLC | $19.54 | 2019 | |
| Abbott Laboratories | $19.06 | 2019 | |
| Glaxosmithkline, LLC. | $12.81 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12.56 | 2020 | |
| Amarin Pharma, INC. | $12.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Perlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.